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             Ulcerative colitis (UC) is a chronic disease of the colon or large intestine that 
causes inflammation and ulceration of the inner lining of the colon and rectum. In 
patients with ulcerative colitis, the body’s immune system overreacts and the body 
mistakes food, bacteria or other internal materials in the colon for an invading substance. 
The immune system attacks the material, thus irritating the colon. Limited knowledge of 
inflammatory conditions coupled with a narrow range of therapeutic options necessitates 
investigating the role of natural products. This study describes the effect of natural 
coconut oil on chemically-induced acute and chronic disease in mice. Ulcerative colitis 
was induced in four groups (5 mice per group) of 10-week-old female C57BL/6 mice by 
exposing them to 2.5-3% dextran sulfate sodium (DSS) for 5 and 29 days in the acute and 
chronic models, respectively. Coconut oil treatment was given via food containing 5% 
coconut oil to three diseased groups in three different regimens: one, preventive group 
receiving treatment prior to disease induction (14 d in acute; 28 d in chronic); two, 
simultaneous group receiving treatment simultaneous to disease induction; and three, 
regular treatment group receiving treatment after the disease induction –until termination 
of the experiment (14 d in acute; 60 d in chronic). Coconut food was replaced by the 
regular chow in the disease and water control groups. Clinical symptoms (diarrhea, occult 
blood, anal bleeding and body weight change) and the size of the isolated colon were 
recorded for comparison between experimental and control groups. Groups receiving 
xiii 
 
coconut food displayed remissions in clinical markers of the disease. Improvements in 
clinical symptoms, histopathology, as well as cytokine activities were observed in both 
models, but the effects were more significant on the basis of standard error in the chronic 
model. 
Keywords: ulcerative colitis, coconut, medium-chain fatty acids, gastrointestinal 
ulcers, natural fatty acids, virgin coconut oil, coconut supplements.
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Chapter 1: Introduction
1.1 What Is Ulcerative Colitis? 
             Ulcerative colitis (UC) is a chronic disease of the colon or large intestine that 
causes inflammation and ulceration of the inner lining of the colon and rectum (Xavier 
and Podolsky, 2007). It can occur in all areas of the colon, although in some people UC 
affects only certain portions of the colon (Itzkowitz et al., 2004). In patients with UC, the 
body’s immune system overreacts. The body mistakes food, bacteria or other internal 
materials in the colon for an invading substance and it signals the immune system to 
attack the material, thus irritating the colon. This irritation triggers a flare in symptoms of 
ulcerative colitis. During a flare, people with ulcerative colitis may have bloody, pus- or 
mucus-filled stools, diarrhea, cramping, abdominal pain and bloating. Polymorphonuclear 
neutrophil infiltration is associated with the primary and central lesion of colitis and 
followed by loss of the epithelium, goblet cells and crypt damage (Malago & Nondoli, 
2008). Ulcerative colitis affects approximately 500,000 people annually in the United 
States, with a peak incidence between the ages of 15 and 25. The disease affects females 
more than males (Hanauer, 1996). The highest incidences of UC are seen in the United 
States, Canada, the United Kingdom and Scandinavia. The northern parts of Europe and 
the United States are much more affected than southern regions. The prevalence of UC is 
higher in people of Ashkenazi Jewish descent, non-Jewish Caucasians, Africans, 
Hispanics and Asians (Fauci, Kasper, Longo, Braunwald, Hauser, Jameson and Loscalzo, 
2008).  
Since the etiology of UC remains unclear, successful treatment strategies targeting large 
sections of the affected population have not been found. In recent years, several clinical 
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trials have been performed to establish the efficacy of different therapies, but nothing 
seemed effective in curing the disease. Patients with prolonged UC are at an increased 
risk for developing colitis-associated cancer (CAC) (Ekbom, 1998; Greten et al., 2004). 
The risk of colon cancer increases with the duration and severity of the disease. 
Approximately 5% of all UC patients are diagnosed with colon cancer (Dey et al., 2010).  
UC is currently treated with medications that include a combination of anti-
inflammatory, immunosuppressive and antibiotic drugs with limited remission and 
significant episodes of side effects; often patients become refractory and seek an 
alternative therapy (Hilsden, 2003).  Side effects of the above drugs, such as kidney 
damage or increased risk of infections from use of immunosuppressive agents are 
common (Kwon and Farrell, 2005; Aharoni et al., 2006). One recent study has shown that 
21% of patients with inflammatory bowel disease (IBD), of which UC and Crohn’s 
disease are the predominant types, resort to the use of complementary and alternative 
medicine, discontinuing their prescribed medicines (Head et al., 2004). Lack of 
efficacious drugs to treat patients with different forms of IBD underscores the need for 
the development of a new and effective alternative therapy.  
1.2 Etiology 
 
(http://www.ulcerativecolitis.us/app/images/causes.gif) 
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The pathogenesis of ulcerative colitis is not well known. However, several factors 
contribute to the development of UC, such as environment, genetic tendency and 
immunology. The major theories include infection, allergy to food component, genetics, 
environmental factors, and immune response to bacteria or other antigens (Neuman & 
Nanau, 2012). In addition, genetic studies and mouse models have emphasized the role of 
genetic predispositions and how they affect interactions with microbial and 
environmental factors, leading to pro-colitogenic perturbations of the host–commensal 
relationship (Khor, Gardet and Xavier, 2011). It is believed that the body’s immune 
system reacts abnormally to the natural gut flora, specifically the bacteria in proximity to 
the mucosal cells of the colon, leading to an increased pro-inflammatory response such as 
the activation of monocytes, macrophages and cytokines.  
Histological evaluations show aggregation of monocytes and macrophages in the 
mucosal lining of colon tissue derived from UC patients. Although the innate immune 
response is primarily involved in initiating colonic inflammation, the role of adaptive 
immunity (T-cell responses) in contributing to UC symptoms is significant (Sartor, 
2006). Mucosal epithelial cells play an important role not only in the development of 
innate immunity but also in the induction of memory pathways of adapted immunity. The 
primary locations where the adapted immune response sets in are at crypts and lymphatic 
follicles (Lukas et al., 2006). One widely held hypothesis on the pathogenesis of UC and 
other IBD is that T-cell (adaptive) immune responses to a subset of commensal enteric 
bacteria are over-expressed in genetically susceptible hosts, where environmental factors 
lead the onset of disease (Sartor, 2006). 
1.2.1 Inflammatory cytokine response. 
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Major inflammatory cytokines produced by activated macrophages include TNF-
α, IL-6 and IL-1β. These cytokines are generally elevated in the colonic mucosa of UC 
patients, and implicated in mucosal damage that occurs in this disorder (Murata et al., 
1995). While the production of regulatory cytokines such as IFN-γ decreases, IL-10 
increases in the case of inflammatory colitis. IFN-γ is a dimerized soluble cytokine that is 
the only member of the type II class of interferons. This cytokine is essential for innate 
and adaptive immunity against viral and intracellular bacterial infections and for tumor 
control. The role of Th17 cells and IL-17 in gut inflammation has been recently examined 
in excellent reviews (Monteleone et al., 2009; Strober and Fuss, 2011). Th17 cells are 
constitutively present in human and mouse intestinal mucosa, and provide defense against 
enteric bacteria. Th17-derived cytokines such as IL-17A, IL-21 and IL-22 promote the 
recruitment of inflammatory cells in the intestinal lamina propria, owing to their ability to 
enhance the synthesis of chemo-attractants and adhesion molecules (e.g., ICAM-1) by 
epithelial and endothelial cells, respectively (Monteleone et al., 2009). In this study, five 
important cytokines associated with inflammatory colitis (TNF-α, IFN-γ, IL-6, IL-1β and 
IL-17) were studied. These cytokines were assayed by cytokine sandwich ELISA 
(enzyme-linked immunoasorbent assay) model using sera and tissue samples (for the 
quantification of site-specific cytokine level) collected from all the experimental and 
control groups of mice. 
1.2.2 Environmental factors. 
Studies show that environmental agents (diet, stress, drugs) are important in the 
initiation of initiate UC disease expression (Sartor, 2006). Recently, several disease-
modifying factors have been identified, such as diet, spices, antibiotics, modern infant 
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nutrition, stress, smoking, highly hygienic and sanitary conditions, use of other drugs, etc. 
(Lukas et al., 2006). In developed countries, living under extremely hygienic conditions 
in early childhood leads to dramatic commensal contact reduction between bacterial flora 
and immuno-competent cells in the bowel. Consequently, the loss of tolerance to 
bacterial (pathogenic) antigens may cause chronic intestinal inflammation later in life 
(Lukas et al., 2006).  
1.2.3 Genetics. 
              Both UC and Crohn’s disease have a complex genetic basis; however, the 
genetic cause is better recognized currently in Crohn’s disease than in UC.  Few genes 
have been identified that are related to the etiology of IBD: four genes with Crohn’s 
disease and one gene (PPARG) with ulcerative colitis. PPARG is a nuclear receptor that 
inhibits NF-κB activity and is responsible for decreased expression in the patients with 
active ulcerative colitis. The genes associated with the pathogenesis of IBD generally 
regulate innate immune responses, mucosal barrier function and bacterial killing (Sartor, 
2006). It is well documented that reactive oxygen species (ROS) activate NF-κB, which 
leads to the generation of pro-inflammatory cytokines and other inducible enzymes, such 
as cyclooxygenase -2 (COX-2) in leukocytes and macrophages (Chandel et al., 2000). 
Chemopreventive and chemoprotective phytochemicals can correct undesired cellular 
functions caused by abnormal pro-inflammatory signal transmissions mediated by NF-κB 
(Surh, 2008). This inflammatory regulator as well as transcription factor exists mainly as 
a heterodimer comprised of subunits of the Rel family p50 and p65; activation of NF-κB 
involves the phosphorylation of I-κBs. The resulting free NF-κB is then translocated to 
the nucleus, where it binds to κB binding sites in the promoter regions of target genes and 
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regulates the expression of pro-inflammatory cytokines, chemokines and (COX)-2. This 
can lead to chronic inflammatory disease such as UC and ultimately to cancer (Chun et 
al., 2004). 
1.3 Epidemiology 
             Epidemiological studies show that the environment and genetics have a role in 
the development of the disease. Ulcerative colitis may occur in people of any age, but 
most often it starts between ages of 15 and 25 and less frequently in older age (Changtai 
et al., 2009). American Jews of European descents are more prone to develop UC than 
the general population. Moreover, females are more susceptible to this disease than 
males, with higher incidence in North America, Scandinavia and the United Kingdom.  
Studies have shown that 20% to 25% of patients may have a close relative with either 
Crohn’s disease or ulcerative colitis (Crohn’s & Colitis Foundation of America, 2013). 
Ulcerative colitis is predominantly found in developed countries and less often found in 
Asia, Eastern Europe, South America and other parts of the developing world (Lee, 
2013). There are significant differences between ethnic groups with some, such as 
Ashkenazi Jews, having higher incidence. It is a worldwide disorder with high-incidence 
areas that include Australia, northern Europe, the United States and United Kingdom. 
Also, there is a higher incidence in northern versus southern regions. A low incidence of 
UC is seen in Asia, Japan, and South America (Changtai et al., 2009).  
1.4 Role of Coconut Oil 
          The role of saturated fatty acids on human health is currently being revisited, and 
this issue is drawing significant attention specifically in inflammatory and metabolic 
disorders (Head et al., 2004). Recently, anti-inflammatory role of coconut oil was 
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examined in some investigations.  Zakaria et al (2011) demonstrated an anti-
inflammatory role of virgin coconut oil in an acute carrageenan-induced paw edema in 
Sprague- Dawley rats but not in a chronic model of inflammation.  Natural coconut 
(Cocos nucifera) oil is a rich source of medium-chain saturated fatty acids (MCFAs), its 
main constituent being lauric acid, a 12-carbon fatty acid. Effects of MCFAs such as 
lauric and caprylic acid have been little studied until very recently (Head et al., 2004).  
1.4.1 Physico-chemical properties. 
           Coconut oil is insoluble in water. Above its melting point, coconut oil is 
completely soluble with non-hydroxylic solvents such as benzene. Also, it is more 
soluble in alcohol than other common fats (oils). It has low iodine content, high medium 
chain fatty acid content and at room temperature (27ºC) it stays in liquid form. Oils are 
generally made up of triglyceride molecules containing tri-esters of glycerol and fatty 
acids. Upon hydrolysis they yield fatty acids and glycerol. The fatty acids can be 
classified on the basis of their molecular size or length of the carbon chain. The majority 
of fats (oils), whether they are saturated or unsaturated or from an animal or a plant, are 
composed of long-chain fatty acids (LCFAs). MCFAs are a type of fat in which three 
saturated fats are attached to glycerol molecule are attached, with each chain comprising 
six to twelve carbon atoms (Babayan, 1988). MCFAs can be found in many foods and 
dietary supplements (Heydnger and Nakhasi., 1996). They have different patterns of 
absorption and utilization than fats such as LCFAs.  
In the process of LCFA absorption, fatty acid chains are cleaved from the glycerol 
with the help of the lipase enzyme. These fatty acids then form micelles that are absorbed 
and reattached to glycerol to travel through the lymph system to the bloodstream. About 
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30%of MCFAs are absorbed in the intestine to reach portal vein directly, which leads to 
fast absorption and utilization of MCFAs than any other type of fat. MCFAs are 
transported without the need for any kind of shuttle to the mitochondria and metabolized 
rapidly in the liver. They do not participate in the biosynthesis and transport of 
cholesterol (Hoahland and Snider, 1943; St-Onge, Ross, Parsons and Jones, 2009).  
The presence of MCFAs in coconut oil makes it different from all other 
commonly consumed fats (oils) and gives it its unique character and healing properties. 
Nearly all of the medium-chain triglycerides used by scientists, researchers and 
pharmaceutical companies come from coconut oil. MCFAs are easily digested and 
absorbed, and thus are commonly used for cosmetic and nutrition purposes.    They 
provide a quick source of energy that is conducive to promote healing. MCFAs are 
natural and vital components of human breast milk, which confers nutrition and 
immunity to newborns. This is why MCFAs are also added to infant formulas.  MCFAs 
are considered essential nutrients for infants as well as for the people with cystic fibrosis 
and IBD (Johnson and Cotter, 1986; Marie et al., 2003).  
1.4.2 Therapeutic Applications and Healing Properties of Coconut Oil 
             MCFAs have been used in other malabsorption syndromes, including small-
bowel syndrome, celiac disease and hepatic disease (Johnson and Cotter, 1986). MCFAs 
may help with weight maintenance in AIDS patients. An enteral formula containing 
85%of fat calories from MCFA (35% of total calories from fat) led to decreases in stool 
fat, number of bowel movements and abdominal symptoms, as well as increased fat 
absorption compared with baseline; however, a LCFA-containing formula showed no 
improvement (Robert, 1978; Nick, 2006). MCFA-containing caloric supplements do not 
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appear to cause weight gain in AIDS patients compared with a control diet.  Studies 
indicate that specific MCFAs, such as lauric and caprylic acid, have an adverse effect on 
the pathogenic microorganisms, including bacteria, yeast and fungi. These fatty acids and 
their derivatives actually disrupt the lipid membranes of the organisms and thus inactivate 
them (Isaacs and Thomas, 1991).  
           Coconut oil is antiviral, anti-fungal and antibacterial. It attacks and inhibits viruses 
that have a lipid coating, such as herpes simplex, HIV, hepatitis C, flu and 
mononucleosis. It is able to kill the bacteria that cause some types of pneumonia, sore 
throats, dental caries, meningitis, gonorrhea, food poisoning, urinary tract infections and 
several other infections (Kabara, 2000). It also inhibits the fungi and yeast that cause the 
various forms of tinea, as well as Candida. MCFAs can reduce mucosal irritation, the 
classic characteristic of irritable bowel syndrome (IBS) and dysbacteriosis (Lim, 1987).  
Approximately 50% of the fatty acids of coconut oil are in the form of lauric acid. 
Lauric acid is known to inactivate viruses and bacteria that are enveloped in a 
phospholipid membrane such as influenza viruses and HIV (Nick, 2006). Coconut 
contains about 75% dietary fiber that is beneficial for colon flora. Reports indicate that 
coconut oil is not accumulated in adipose tissues and thus not considered a contributing 
factor to obesity. It tends to increase the HDL and decrease the LDL: HDL ratio 
(Assuncao et al., 2009).  
Research also shows that coconut oil lowers cholesterol by stimulating thyroid 
function. In the presence of thyroid hormone, cholesterol is converted to pregnenolone, 
progesterone and DHEA, reducing the risk of cardiovascular disease, dementia, cancer, 
obesity, aging and chronic degenerative diseases (Cohen et al., 1986; Lim, 1987). This 
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shows the thyroid suppressive and immunosuppressive effect of coconut oil. Thus it can 
be seen that MCFAs exhibit different metabolic activities than saturated or unsaturated 
long- and short-chain fatty acids. 
            Limited knowledge of the physiopathology of ulcerative colitis, coupled with a 
narrow range of therapeutic options, necessitates investigating the role of natural products 
as alternative therapies. We hypothesized that coconut oil containing medium-chain fatty 
acids will affect clinical symptoms and colon histopathology involved in ulcerative colitis 
by modulating inflammatory responses in the diseased mice. This study includes the 
effect of coconut oil in acute and chronic models of the disease, based on laboratory 
mice. The objectives of this research were: I. to chemically induce ulcerative colitis in 
experimental and control groups of age/gender-matched mice (C57-BL6/J), II. to monitor 
clinical symptoms, III. to evaluate proinflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-
1β and IL-17) in sera and colonic tissues and, IV. to assess colonic tissues for histological 
changes in treatment and control groups. 
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Chapter 2: Materials and Methods 
2.1 Acute Model 
2.1.1 Induction of colitis by DSS administration. 
Five groups of 10–12-week-old female mice (C57-BL6/J), 5 mice per group, were 
housed in standard mouse cages with a normal supply of food (Lab Diet from PMI 
Nutrition International, LLC, St. Louis, MO) and drinking (tap) water. These mice were 
observed for 72 hours before starting the experiment. All mice groups were maintained in 
the designated room at 25–28°C with 12-hour light/dark cycle.  
Oral administration of DSS was given as follows: On day one, the mice were 
weighed and numbered. Four groups of mice exposed to 3% (w/v) DSS were selected as 
disease groups. The water bottle of each mouse cage was filled with 100 ml of 3% DSS 
solution and was given to these mice ad libitum (consumption calculated at the rate of 5 
mL DSS solution per mouse per day). Vehicle control mice received the same drinking 
water without DSS, and this group was designated the healthy control group. A critical 
step was to mount the bottle lids properly and ensure that the tips were not blocked. The 
DSS solution remaining in the water bottles was emptied at days three and five, and the 
bottles were refilled with fresh DSS solution of the same concentration. The remaining 
DSS solution was replaced by tap water on day seven (Wirtz et al., 2007), and kept 
available to the mice until the last day of the experiment. 
2.1.2 Coconut food treatments. 
             Customized coconut food (Lab Diet containing 5% of virgin coconut oil) was 
purchased from PMI Nutrition International, LLC. Coconut oil treatment was given to 
three diseased groups of mice in three different regimens, one, preventive group receiving 
treatment 14 d prior to disease induction; two, simultaneous group receiving treatment 
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simultaneous to disease induction; and three, regular treatment group receiving treatment 
after the disease induction –until termination of the experiment, day 14. Coconut food 
was replaced by the regular chow in the disease and healthy control groups. A general 
timetable for the acute DSS and coco food administration model can be found in Table 2. 
2.2 Chronic Model 
 2.2.1 Induction of colitis by DSS administration. 
            The chronic DSS colitis model started on day zero with numbering and weighing 
of mice. The same day, the water bottle of each mouse cage was filled with 2.5% DSS 
solution, with the exception of the healthy control group (vehicle control). On day three, 
the water bottles were emptied of DSS and refilled with tap water until day 8. Four cycles 
of DSS and water were repeated as above. (Wirtz et al., 2007).  
2.2.2 Coconut food treatments. 
Coconut oil treatment was given to the three diseased groups of mice in different 
regimens, one, preventive group receiving treatment 28 days prior to disease induction; 
two, simultaneous group receiving treatment simultaneous to disease induction; and 
three, regular treatment group receiving treatment after the disease induction –until 
termination of the experiment, day 60. Coconut food was replaced by the regular chow in 
the disease and healthy control groups. A general timetable for the chronic disease 
induction and coconut food intervention model can be found in Table 3. 
2.3 Clinical Markers 
2.3.1 Body weight measurement.  
Body weight of mice in all experiments was measured in grams every other day 
from day zero to the experiment termination day. The percent change in body weight was 
calculated by the following formula:
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100% 

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BodyWeight  
2.3.2 Fecal occult blood test and stool consistency. 
A product called ColoScreen ES Lab Pack (Helena Laboratories, Beaumont, TX) 
was used to evaluate the presence of fecal occult blood on every other day at the time of 
body weight measurements. Two random measurements per group of mice were taken to 
check the clinical markers. A fresh stool sample was collected and placed in the test area 
of the ColoScreen kit. Two drops of reagent from the ColoScreen kit was placed on the 
area to be used as a reference and the stool sample test area, then the results were 
observed for the color change according to the amount of blood present in the stool. 
Results were recorded and the presence or absence of fecal blood was used in the 
determination of the disease activity index. Values were averaged over the entire period 
of the experiment. 
In the process of making decisions for experiments, the stool of each group was 
observed and scored on a scale ranging from 0 to 2 based on the degree of severity of 
fecal blood and stool consistency: 0 = normal solid, no color change in samples; 1 = mild, 
color change in samples with soft stool; 2 =severe, color change in samples with diarrhea, 
loose stool sticking to the cage wall and mouse body, blood spots scattered around anus 
and the presence of rectal prolapse.  
2.3.3 Liquid consumption. 
The measurement of the amount of liquid (tap water; DSS solution) consumed by 
each group was recorded and analyzed. Each group received an initial amount of 100 mL 
of liquid (DSS solution or water), and the amount of liquid consumed was recorded on 
the day of replacement. Adult mice are known to consume generally 5 mL of drinking 
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water per day when given ad libitum. An average consumption per group was calculated 
for the period of DSS exposure. 
2.3.4 Euthanasia, isolation and storage of colon. 
At the termination of the experiment, the mice from each group were euthanized 
using an overdose of the inhalant anesthesia Isofluorane (Baxter Healthcare Corporation, 
99.9% Isofluorane/mL) administered in a euthanasia chamber. After ensuring death, each 
mouse was dissected for isolation of colon (distal portion of large intestine). Isolated 
colon lengths were measured in centimeters. Isolated colons were stored in histology 
tubes with 10% neutral formalin solution prior to histological analysis. Average colon 
lengths with standard errors from each group were determined and plotted.  
2.3.5 Histology. 
Paraffin-embedded tissues were sectioned at a thickness of six to seven microns 
using a rotary microtome. The sectioned ribbons containing colon sections were then 
stained by hematoxylin and eosin (H&E) for histological evaluation of colonic damage 
(100x and 400x magnification). In a typical tissue, nuclei are stained blue by the 
hematoxylin while the cytoplasm and extracellular matrix show varying degrees of pink 
staining from the eosin. Nucleoli stain with eosin (Fischer et al., 2008). The staining 
protocol is shown in Table 5. 
2.3.6 Drawing blood and tissue from euthanized mice. 
After euthanasia, a 1-ml tuberculin syringe with 25 and ½ guage needle was used 
to draw blood directly from the heart of each mouse by opening the thoracic cage. A new 
sterile syringe and needle was used for each replicate. The blood from each replicate was 
placed in a 1.5 mL autoclaved micro-centrifuge tube. The tubes were stored in a 
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refrigerator at 4°C overnight. Colons were collected terminally, measured for their gross 
length and flushed with sterile Type I purified water. Tissue samples (each 3 mm) from 
each replicate were collected and incubated with RPMI-1640 media in a sterile cell 
culture plate for 72 hours at 37° C. Blood and tissue samples were then centrifuged twice 
at the rate of 3,000 RPM for 10 minutes. Sera and tissue sample extracts were collected 
and placed into new autoclaved micro-centrifuge tubes. The sera and tissue extract 
samples were stored in the -20
°
C freezer until used in ELISA. Serum and tissue extract 
samples were used for testing the concentrations of TNF-α, IFN-γ, IL-1β, IL-6 and IL-17 
in experimental and control groups. 
2.4 Enzyme-Linked Immunoasorbent Assay (ELISA) 
         Anti-mouse TNF-α, IFN-γ, IL-1β, IL-6 and IL-17 were procured from R&D 
Systems, Inc. (Minneapolis, MN) For the TNF-α capture antibody, 144 μg/mL of goat 
anti-mouse TNF-α was reconstituted with 1.0 mL of PBS. For the IFN-γ capture 
antibody, 720 μg/mL of rat anti-mouse IFN-γ was reconstituted with 1.0 mL of PBS. For 
the IL-17 capture antibody, 360 μg/mL of goat anti-mouse IL-17 was reconstituted with 
1.0 mL of PBS.  All capture antibodies, detection antibodies, and standards were allowed 
to rest for a minimum of 15 minutes and were gently agitated prior to making dilutions. 
Reagents and solutions were prepared in accordance with the instructions in the R&D 
Systems kit. The procedure is outlined in appendix. 
2.5 Blood Flow Cytometry 
   Monocyte phenotyping.  
Monocytes were phenotyped as classic (CD14+/CD16-) or inflammatory 
(CD14+/CD16+) according to a modified published protocol (Navalta et al., 2011). All 
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antibodies and buffers were obtained from eBioscience (San Diego, CA, USA). Briefly, a 
20 µL sample of blood from each mouse was added to a 250 µL antibody panel 
containing titered quantities of anti-mouse CD14-FITC and anti-mouse CD16-PE in Flow 
Cytometry staining buffer. The sample was incubated for 30-min in the dark and then 
centrifuged for 5-min. After decanting and vortexing thoroughly, 300 µL of RBC lysis 
buffer was added and the sample was incubated for 15-min before 300 µL of PBS was 
introduced. The sample was centrifuged for 10-min, decanted, and then vortexed 
thoroughly prior to analysis by flow cytometry (BD Accuri, C6, San Jose, CA, USA). An 
initial monocyte gate was established according to forward- and side-scatter properties, 
and then populations of classic and inflammatory monocytes were identified. Each 
replicate sample was processed in duplicate and values were averaged to obtain the final 
result.  
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Chapter 3: Results 
3.1Clinical Features 
3.1.1 Acute Disease Model 
3.1.1.1 Liquid consumption 
Liquid consumption by each group during the exposure to DSS was measured to 
ensure that each diseased mouse was exposed to the equivalent quantity of the disease-
causing chemical, DSS. Figure 1B shows an average consumption of water or DSS 
solution by a group of 5 mice, averaged over the period of DSS exposure. All DSS 
groups consumed about the same quantity of solution (no significant difference as seen 
by the standard error) varying from 38 to 60 mL. However, mice in the healthy control 
group displayed a significantly higher consumption of water, up to 75 mL.  
3.1.1.2 Body weight change 
          Figure 2A shows the percent change in mouse body weight over the course of the 
experiment.  Body weight started declining after three days of DSS exposure in all groups 
except in healthy and preventive groups. The loss in body weight measured up to 35% in 
the simultaneous group, followed by 25% in the treatment group. However, the 
preventive group displayed a different pattern, the weight decline started late, after 6 
days, following a significant gain at day three. The drop in weight in this group reached 
13%, and returned to 5% at day 11. However, the weight gain in this group was not 
significantly different from the disease control by the end of the experiment. 
 3.1.1.3 Diarrhea and fecal occult blood  
        Figure 1A displays the severity of diarrhea and fecal occult blood (averaged over the 
entire period of the experiment) in different test and control groups (scale in Table 6). It 
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can be seen that the disease control had a severity value of >2, while treatment groups 
had a severity index of < 2. Mice in the preventive group scored a significantly less value, 
<1.5, than mice in the disease control and other test groups. Obviously, ice in the healthy 
control group measured zero on this scale having no DSS exposure. 
3.1.1.4 Colon size 
        Colons from all groups of mice were isolated and measured (size) after termination 
of the experiment. Figure 1C shows that mice in the healthy control group had the largest 
average colon size of 9 cm while mice in the disease control group had the smallest 
average size of 5.6 cm. All treatment groups had a significantly larger average colon size 
than disease control but significantly smaller than that of the healthy control.  
 3.1.1.5 Disease activity index 
        A disease activity index was prepared on the basis of a combined scale including 
disease symptoms such as body weight loss, colon length, fecal occult blood and stool 
consistency see (Table 6). Mice in the disease control group displayed a maximum value 
of two on this index. This value dropped to a level of one at the end of the experiment. 
The calculated disease index in disease control and treatment groups was not significantly 
different. As expected mice in the healthy control group scored zero, having no 
symptoms on this index (Figure 2B).          
3.1.2 Chronic Disease Model 
3.1.2.1 Body weight change 
         With the induction of chronic disease, the weight of mice in some test groups and in 
the disease control group decreased significantly (Figure 3A). Around day 30, maximum 
weight loss, approximately 28%, was observed in the simultaneous test group, followed 
by approximately 15 % in treatment groups which was similar to mice in the disease 
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control group. However, mice in the preventive test group suffered no weight loss after 
DSS exposure.  After the end of the last cycle of DSS exposure, an increase in weight 
toward weight restoration was significant in the test groups as well as in the disease 
control group. However, the rate of weight gain in the preventive group was significantly 
greater than in any other groups including the healthy control. The weight in the 
preventive group gradually rose over the entire period of the experiment until day 60 with 
a final gain of <20% over the initial weight. The preventive test groups had the most 
pronounced improvement, with average body weight exceeding the initial average body 
weight (the weight before any treatment). This group demonstrated the possible 
preventive potential of the treatment. 
3.1.2.2 Diarrhea & fecal occult blood.                                                                        
        Figure 3C indicates the severity of diarrhea and fecal occult blood in different 
groups. Values for each group were averaged over the entire period of the experiment. 
Disease control mice measured 2 to 2.5; mice in test groups scored 1 to 1.5 on this scale 
of severity (Table 6). No significant differences were observed among the test groups.                                                                         
3.1.2.3 Colon length.                                                                                                                   
        Figure 3D indicates the average length of isolated colon from each group at the end 
of the experiment. It can be seen from this figure that the colons of mice in the preventive 
group were restored to the size observed for healthy control mice, while colon lengths in 
simultaneous and treatment groups were not significantly different than in the disease 
control group. Figures 4(A-E) show photographs of isolated colons of replicates from 
each group. 
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3.1.2.4 Disease activity index. 
       Figure 3B displays the disease index value based on a combined scale for different 
parameters (Table 6). It can be seen in Figure 3B that mice in the disease control group 
showed an average value of 3 on this index at about day 42 and then fell to 2 by the end 
of the experiment. No test groups exceeded a value of 2 on the disease activity index at 
any time during the disease induction, and declined back to a value of 1at the end of the 
experiment. 
3.2 INFLAMMATORY MARKERS                                                                                      
 3.2.1Acute disease model                                                                                                       
3.2.1.1 TNF-α.                                                                                              
           Figure 6A shows the standard curve for TNF-α. Figures 6B and C display TNF-α 
concentrations  in the blood and colon tissue sample of each group. The differences in the 
level of blood TNF-α  were not significant among the experimental groups or between 
the experimental groups and the disease control (Figure 6B). However, some individual 
mice in the disease control group had the maximum value of 200 pg/mL, while no test 
group ever exceeded 100 pg/mL.The pattern in tissue samples was different, where 
disease control yet exhibited 200 pg/mL (Figure 6C), while test groups never exceeded 
100pg/mL. However, the difference among test groups was not significant. 
3.2.1.2 IFN-γ (acute model). 
Figure 7A displays the IFN-γ standard curve. Levels of IFN-γ in either blood or 
tissue samples were not detectable (Figures 7B&C, not shown). 
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3.2.1.3 IL-17. 
Figure 8A, shows the IL-17 standard curve. Figure 8B displays the mean blood 
concentrations of IL-17 in different groups. The level of IL-17 was higher in preventive 
and treatment groups, identical to healthy control, when compared to the disease control 
group. However, no significant difference was found between the disease group and the 
simultaneous test group (Figure 8B). Figure 8C shows the levels of IL-17 concentration 
in tissue samples. A pattern similar to blood samples was observed in the tissue samples. 
Mice in the preventive group showed the higher levels of IL-17, up to 115 pg/mL (see 
Fig 8C). Mice in the preventive and test groups show significantly increased levels of IL-
17 compared with all other groups. 
3.2.1.4 IL-1β. 
The IL-1β standard curve is shown in Figure 9A. Figure 9B shows the mean 
levels of IL-1β in blood samples from each group. No detectable IL-1β was observed in 
any test groups or in the healthy control groups, but mice in the disease control shows  
IL-1β activity, which varied greatly among the replicates. Figure 9C exhibits the quantity 
of IL-1β in tissue samples where DSS control represented a higher activity of 300 pg/mL. 
No test group or the healthy control group had any detectable level of this cytokine 
(Figure 9C).  
3.2.1.5 IL-6. 
Figure 10A shows the IL-6 standard curve. Figure 10B indicates the mean levels 
of IL- 6 in blood in different groups. It can be seen in this figure that mice in the disease 
group had significantly elevated levels of IL-6 compared to mice in water control, 
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preventive, and simultaneous test groups. However, mean levels of IL-6 were not 
significantly different between the disease control and the treatment test group.  The IL-6 
concentration level in colon tissue was not tested due to insufficient tissue samples. 
3.2.2 Chronic Model 
3.2.2.1 Activated monocytes in circulating blood. 
Figure 5 shows the percentages of activated monocytes percentage in different groups. A 
maximum percentage (approx. 15%) of activated monocytes was observed in the disease 
control, while significantly lower levels (<2 %) were detected in all other groups. All 
groups of treated mice (preventive, simultaneous, treatment) had levels of activated 
monocytes similar to healthy control mice. Mice in the preventive group, showed the 
lowest overall percentage of activated monocytes.  
3.2.2.2 TNF-α.  
Figure 11A shows the standard curve trend for TNF-α concentration. Figure 11B 
indicates the mean blood levels of TNF-α. This cytokine was undetectable in test groups, 
preventive and simultaneous, as well as healthy control group. However, the level of 
TNF-α was high in the disease control (approximately 50pg/mL) and not significantly 
different than in treatment test group.   Figure 11C indicates the tissue level of TNF-α in 
different mouse groups. Similar to blood levels, the tissue levels of this cytokine were 
undetectable in preventive and simultaneous test groups as well as the healthy control. 
Mice in the disease control group showed a high level (about 55 pg/mL) of TNF-α.   
3.2.2.3 IFN-γ. 
Figure 12A shows the IFN-γ standard curve. Figures 12B and C indicate the blood 
and tissue levels of IFN-γ, respectively, in different groups. Figure 12B shows 
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significantly lower blood levels of IFN-γ in the preventive test group compared to the 
disease control group, levels in the simultaneous and treatment groups being 
undetectable.  A similar pattern was observed in the tissue level of IFN-γ in different test 
groups and control groups (Figure 12C). 
3.2.2.4 IL-17.  
Figure 13A shows the IL-17 standard curve. Figure 13B indicates the 
concentration of IL-17 in blood sample from each group of mice. The level of IL-17 was 
higher in test groups and in the healthy control group than in the DSS group. The 
preventive group had a maximum level of 140 pg/mL, a level which was significantly 
different than that of disease control mice. However, there was no significant difference 
in IL-17 levels between other test groups and both controls (Figure 13B). Figure 13C 
shows the level of IL-17 concentration in tissue samples. In figure 13C, it can be seen 
that preventive and simultaneous test groups had significantly higher levels of IL-17 
relative to disease and healthy controls. However, the treatment group was not 
significantly different than the control groups.   
3.2.2.5 IL-1β.  
Figure 14A shows the IL-1β standard curve. Figure 14B indicates the levels of IL-
1β in blood samples of different groups, where the levels were not detectable in any 
group. A similar pattern can be seen in tissue samples of different groups (Figure 14C). 
3.2.2.6 IL-6.  
Figure 15A displays the IL-6 standard curve. Figure 15B shows the mean levels 
of IL- 6 in blood samples from different groups of mice. Figure 15B indicates that the 
disease group had a significantly higher concentration of IL-6 than the healthy control 
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group, preventive and treatment test groups. However, this level was not significantly 
different from the simultaneous test group.  Figure 15C indicates that the levels of IL-6 
(tissue) in the healthy control and test groups were significantly lower than the disease 
control group. 
3.3 HISTOPATHOLOGY 
3.3.1 Acute model. 
 Figures 16A and B show the colonic H-E sections of healthy control mice at 
magnifications of 100x and 400x, respectively. The cellular structures appear intact and 
distinct, more conspicuous at a higher magnification. The mucosa, delineated from the 
submucosa, appears intact with crypts and goblet cells.  Aggregates of darkly stained 
monocytes were not present. These sections exhibit some thin cracks due to drying and 
sectioning defects. 
Figures 17A and B show the colonic H-E sections of mice in the disease control 
group at magnifications of 100x and 400x, respectively. These sections exhibit fissures 
and destruction of colonic mucosa and intense monocyte aggregation (stained in blue) in 
different parts of the tissue. At a higher magnification, the loss of crypts and goblet cells 
in the mucosa can be seen (Figure 17B). Figures 18A (100x) and B (400x) show a 
simultaneous test group colonic section structure. Both images show intact crypts, less 
mucosal damage, some goblet cell formation (the white round structures between the 
cells), but dense monocytic aggregation.  
Figures 19A (100x) and B (400x) display a treatment test group colonic tissue 
structure. Both images indicate less mucosal damage and clear goblet cell formation, with 
less monocytic aggregation.  
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3.3.2 Chronic model. 
Figures 20 (400x) displays a DSS control group tissue structure for the chronic 
model. This image indicates  substantial mucosal damage followed by the loss of crypts 
and goblet cells, irregular cellular structure and dense aggregation of monocytes.  
Figures 21A and B show the preventive test group tissue structure for the chronic 
model at magnifications of 100x and 400x, respectively. In both images, the cellular 
appearance is distinct and intact, there is some goblet cell formation andonly low levels 
of  monocyte aggregation are present.  
Figures 22A and B show the simultaneous test group tissue structure for the 
chronic model at magnifications of 100x and 400x, respectively. In this section, the 
histological pattern is similar to that observed in the preventive group of the chronic 
disease model. Formation of distinct and intact cellular structures and goblet cells, with 
less evidence of monocyte aggregation is visible. 
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Chapter 4: Discussion 
         In this investigation, DSS-induced disease models (acute and chronic) of ulcerative 
colitis were used to examine a putative role for natural coconut oil in disease 
amelioration. DSS-induced colitis is one of the most commonly used models that mimic 
aspects of human inflammatory bowel diseases (Qualls et al., 2009). The literature 
indicates the use of DSS in a range of 1.5- 4% by various researchers (Dey et al., 2010). 
Kotakadi et al, (2008) used 1% DSS to induce acute and chronic colitis while Singh et al 
(2010) used 3% to induce colitis in mice. In the present investigation, 3% DSS was used 
to cause acute colitis, while 2.5% DSS was used to cause chronic colitis. Symptoms of 
ulcerative colitis manifested in the onset of diarrhea, fecal occult blood and body weight 
loss rapidly in both acute and chronic disease model. 
4.1 Acute model 
          The effect of coconut oil treatment on symptoms such as diarrhea and fecal occult 
blood was not pronounced between disease control and test groups. However, mice in the 
preventive group displayed significant improvement in these clinical symptoms. The 
restoration of colon size, however, was significant in all treatment groups as compare to 
disease control group. The loss in body weight could not be regained in any of the test 
groups as a result of coconut treatment.  DSS-induced colitis has been shown to result in 
loss of body weight (Dey et al., 2010; Singh et al., 2010). Therefore, treatment aims at 
controlling weight loss in addition to improving other clinical symptoms, but coconut 
treatments were not observed to reverse the weight loss. The administration of American 
Ginseng and Ginkgo biloba extract resulted in a significant restoration of body weight 
(Kotakadi et al., 2008a; b). The disease activity index representing effects of coconut oil 
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in different groups can be seen in (Figure 2B). This figure shows no significant difference 
between disease control and test groups. The disease index reflects an average score 
based on a combination of disease parameters including body weight change.  As there 
was no change in the body weight loss between groups, there was a negligible effect of 
coconut oil on disease index. Zakaria et al (2011), however, demonstrated an anti-
inflammatory role of virgin coconut oil in an acute carrageenan-induced paw edema in 
Sprague-Dawley rats but not in a chronic model of inflammation. The use of dietary 
phenethylisothiocyanate was, however, observed to impact the disease index positively in 
UC (Dey et al., 2010). Ginkgo biloba was also shown to affect inflammation and 
ulceration scores in colitis (Kotakadi et al., 2008). The negligible effect of coconut oil in 
the acute colitis in present study may have occurred due to the severe damage caused by 
3% DSS and the suboptimal dose (60mg/kg) of coconut oil. It is likely that the lower 
dose of DSS used in the cited studies resulted in less severe damage to the colonic 
epithelium as compared to the 3% of DSS used in this study. Further, a recent 
investigation indicated that the severity of colitis can differ between similar DSS 
preparations of the same molecular weight range (Sigeki et al., 2012). This difference in 
colitogenic properties may be affected by the total sulfur content of each DSS 
preparation. The DSS (MP Biomedicals), used in the present investigation, was reported 
to cause the most severe disease and weight loss (Sigeki et al., 2012).
 
           Several mechanisms for DSS-induced colitis have been proposed in the literature. 
The rapidity of the acute model suggests that adaptive immunity is not pivotal to the 
development of lesions or crypt erosion in the colonic mucosa (Sigeki et al., 2012). 
Furthermore, no precise inflammatory mechanisms have been identified which contribute 
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to the genesis of acute lesions. Similar DSS-induced lesions were also observed in the 
case of severe combined immuno-deficient mice, thus ruling out any involvement of B or 
T cells in the pathology (Sigeki et al., 2012).
 
The resultant colonic inflammation is 
predominantly driven by innate cell types. 
          The cytokine responses characterizing inflammatory colitis are the key physiologic 
aliments that govern the initiation, evolution, and ultimately, the resolution of such 
inflammatory conditions (Strober and Fuss, 2011).  Therefore, this study also included 
measurements of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-17, IL-1β, and IL-6) in 
blood and colon tissue samples. Various studies have demonstrated the increased 
activities of TNF-α, IFN-γ, IL-17, IL-1β, and IL-6 in blood and colon tissue samples 
(Dey et al., 2010; Singh et al., 2010) of mice suffering from an inflammatory colitis. In 
the present study the level of TNF-α in test groups was not different than that of the 
disease control group when measured in blood samples. The pattern in tissue samples did 
differ in that, test groups had significantly lower concentrations of TNF-α relative to the 
disease control group. While IL-1β was not detectable in any blood samples, its level was 
high in the tissue samples of mice in disease control group. Test groups, however, had 
undetectable tissue levels of this cytokine. Dey et al. (2010) reported the attenuation of 
IL-1β production in the colons of PEO- treated animals. Blood and tissue levels of IL-17 
was higher in some test groups–preventive and treatment–identical to healthy control and 
when compared to disease control. When IL-6 was measured in blood samples, the levels 
were different in disease control and some test groups, preventive and simultaneous 
groups with a significantly lower level. Singh et al (2010) demonstrated the role of 
resveratrol in the amelioration of inflammation in diseased mice by the reduced activities 
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of pro-inflammatory cytokines.  A partial histological restoration of damaged colonic 
tissues was observed in some groups of mice treated with coconut oil. Colon mucosa of 
treated mice had lower disruptions than in disease control group; however, not 
comparable to healthy control group. The differential activities of pro- inflammatory 
cytokines may have caused a partial attenuation of clinical symptoms as well as colon 
histology in coconut treated mice in this study.  However, preventive role of dietary 
medium chain triglycerides was recently demonstrated in an acute model of TNBS- 
induced colitis in rats (Kono et al, 2003 and 2010). 
4.2 Chronic model 
            In the current study coconut oil treatment resulted in a significant suppression of 
clinical symptoms of ulcerative colitis in this disease model. In addition to improvements 
in diarrhea and fecal occult blood, body weight was also significantly improved in the 
preventive test group. In this group of coconut oil treated mice weight loss was not only 
regained but weight increased gradually over the entire period of the experiment with a 
final gain of >20% (over the initial weight) at the end of the experiment. Weight gain in 
this group even surpasses the weight gain in the vehicle control group (Figure 3A). 
However, body weight change was not significantly different in other groups of treated 
mice relative to the disease control group. The effect on the isolated colon size in test 
groups was also pronounced under the coconut oil treatment. The overall effect of 
coconut oil treatment on the above clinical symptoms was reflected in disease activity 
index (Figure 3B). From the disease activity index it can be seen that the value always 
remained significantly lower in treatment groups than in disease control group. The 
coconut oil treatment effects observed in this study compare well with the amelioration 
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caused by resveratrol and phenethylisothiocyanate in previous studies (Singh et al 2010 
& Dey et al, 2010). The activity of proinflammatory cytokines in the mice in chronic 
model exhibited a different pattern (Figures 11A-15C) than in the acute model. Levels of 
TNF-α and IFN-γ were significantly decreased in mice in treatment groups compared to 
mice in the disease control group. Treated mice and healthy control mice had 
undetectable levels of TNF-α. The dramatic decrease in TNF-α concentration in treatment 
groups suggests a positive effect of coconut oil intervention in this model. A significant 
reduction in the activity of TNF-α was demonstrated in TNBS- induced colitis in rats 
following a diet enriched with medium chain triglycerides (Kono et al, 2010). TNF-α 
plays a key role in colitis (Luo et al 2010 & Dey et al, 2010).  Coconut oil treatment 
caused a similar reduction in the blood and tissue levels of IL-6 in treated mice.  
Proinflammatory cytokines such as TNF-α, IFN-γ, IL-6, IL-1β are generally over 
produced during inflammatory bowel disease. Blocking IL-1 and TNF-α has been highly 
successful in patients with rheumatoid arthritis, inflammatory bowel disease, graft-vs.-
host disease (Strober & Fuss, 2011). The activity of IL-17 exhibited an interesting pattern 
where mice receiving treatment, particularly preventive group, had an elevated level 
relative to disease control, comparable to healthy control. Particularly tissue levels of IL-
17 were significantly greater in preventive and simultaneous groups as compared to the 
levels in healthy control. The role of IL-17 in colitis is yet unclear and conflicting results 
have been reported (Monteleon et al, 2009; Strober & Fuss, 2011). It has been shown that 
IL-17F deficiency results in reduced colitis, indicating that IL-17F has a pathogenic role 
in colitis. IL-17A null- mice develop more severe disease, suggesting a protective role. It 
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appears that TH-17 lymphocytes secret IL-17 F or IL-17 A/ IL-17 based on the mucosal 
internal milieu (Monteleone et al, 2009).  
            It was recently shown that the genotoxic damage in colitis extends beyond the site 
of inflammation to circulating leukocytes and erythroblasts in the bone marrow, 
manifesting a systemic effect (Westbrook et al, 2009). Therefore, circulating monocytes 
were phenotyped as classic (CD14+/CD16-) or inflammatory (CD14+/CD16+) 
monocytes using flow cytometry in this study (Figure 5). The percentage of circulating 
inflammatory monocytes in DSS-disease control mice was significantly different from 
the levels of inflammatory monocytes in the treatment groups and in the vehicle control 
group (Figure 5). The percentage of inflammatory monocytes was significantly less (7-
fold) in treatment groups, as compared to the disease control group.  Activated monocyte 
percentage in treated mice was not significantly different than healthy controls.  In the 
preventive group, the percentage of activated monocytes was even lower than in healthy 
controls (Figure 5). Inflammatory monocytes are rapidly recruited to sites of 
inflammation, but their excessive and/or prolonged recruitment hinders the resolution of 
inflammation and is a hallmark of numerous diseases including ulcerative colitis (Shi and 
Pamer, 2011). It is possible that coconut oil interferes with monocyte recruitment 
reducing total counts during the treatment period, resulting in a significant reduction in 
the disease index in this model. Monocytes play a pivotal role in the inflammatory 
cascade and are a major source of both pro- and anti-inflammatory cytokines. They are 
intimately involved in tissue damage and repair and an imbalance of these processes may 
have detrimental consequences, as in ulcerative colitis (Shi & Pamer, 2011).  
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             Random histological samples of the colorectal region were compared between 
disease control and treatment groups. Coconut oil treatment resulted in restoration of 
crypts, goblet cells and sub-mucosa. Colon samples from treated mice also exhibited less 
monocyte aggregation. These effects correlate with an improvement in the size of the 
colon in treated mice. The changes in colitis histopathology under the influence of 
coconut oil are consistent with the results of resveratrol and phenethylisothiocyanate 
treatments. Similar improvements were reported in rats suffering from TNBS- induced 
colitis on supplementation of dietary medium chain triglycerides (Kono et al, 2010).  
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Chapter 5: Conclusion 
Results of the present study clearly indicate the positive impact of coconut oil in 
the physiology and pathogenesis of ulcerative colitis. The suppression of clinical 
symptoms, inflammation, and colon histology restoration under the effect of coconut oil 
treatments was more pronounced in mice suffering from chronic ulcerative colitis. This 
study strongly suggests that coconut oil has a disease preventive role in the chronic 
disease model. Body weight gain and the observed attenuation in pro- inflammatory 
cytokine levels reinforce the preventive role of the coconut oil. However, an elaborate 
study involving a large number of animal replicates is required for the confirmation of 
these effects.  
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FIGURES 
Acute Model 
 
     
                                   Figure 1A. Fecal occult blood (acute model) 
 
 
Figure 1B. Liquid consumption (acute model) 
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Figure 1C. Length of isolated colon (acute model) 
 
Figure 2A. Percent change in body weight of mice (acute model) 
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Figure 2B. Disease activity index (acute model) 
 
 
 
Figure 3A. Percent change in body weight of mice (chronic model)    
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Figure 3B. Disease activity index (chronic model) 
 
 
 
Figure 3C. Fecal occult blood (chronic model) 
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Figure 3D. Length of isolated colon (chronic model) 
 
 
Figure 4A. Colon isolated from healthy control group (chronic model) 
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Figure 4B. Colon isolated from Disease control group (chronic model) 
 
Figure 4C. Colon isolated from preventive group (chronic model) 
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Figure 4D. Colon isolated from simultaneous group (chronic model) 
 
 
 
Figure 4E. Colon isolated from treatment group (chronic model) 
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Figure 5. Blood flow cytometry (chronic model) 
 
 
 
Figure 6A. TNF-α standard curve (acute model) 
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Figure 6B. Blood TNF-α concentrations (acute model) 
 
 
 
  
Figure 6C. Tissue TNF-α concentrations (acute model) 
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Figure 7A. IFN-γ standard curve (acute model) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7B. Blood IFN-γ concentrations (acute model; data not shown) 
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Figure 7C. Tissue IFN-γ concentrations (acute model; data not shown) 
 
 
 
 
 
Figure 8A. IL-17 standard curve (acute model) 
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Figure 8B. Blood IL-17 concentrations (acute model) 
 
 
  
Figure 8C. Tissue IL-17 concentrations (acute model) 
 
 
46 
 
 
 
Figure 9A. IL-1β standard curve (acute model) 
 
 
  
Figure 9B. Blood IL-1β concentrations (acute model) 
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Figure 9C. Tissue IL-1β concentrations (acute model) 
 
 
 
 
Figure 10A. IL-6 standard curve (acute model) 
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Figure 10B. Blood- IL6 concentrations (acute model) 
 
 
Figure 11A. TNF-α standard curve (chronic model) 
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Figure 11B. Blood TNF-α concentration (chronic model) 
 
 
  
Figure 11C. Tissue TNF-α concentration (chronic model) 
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Figure 12A. IFN-γ standard curve (chronic model) 
 
  
Figure 12B. Blood IFN-γ concentration (chronic model) 
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Figure 12C. Tissue IFN-γ concentration (chronic model) 
 
 
 
 
Figure 13A. IL-17 standard curve (chronic model) 
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Figure 13B. Blood IL-17 concentration (chronic model) 
 
 
 
     
Figure 13C. Tissue IL-17 concentration (chronic model) 
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Figure 14A. IL-1β standard curve (chronic model) 
 
 
 
  
Figure 14B. Blood IL-1β concentration (chronic model) 
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Figure 14C. Tissue- IL-1β concentration (chronic model) 
 
 
 
 
Figure 15A. IL-6 standard curve (chronic model) 
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Figure 15B. Blood IL-6 concentration (chronic model) 
 
 
 
  
Figure 15C. Tissue IL-6 concentration (chronic model) 
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Figure 16A. Healthy control, acute and chronic model (100x) 
 
Figure 16B. Healthy control, acute and chronic model (400x) 
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Figure 17A. Disease control, acute model (100x) 
 
 
Figure 17B. Disease control, acute model (400x) 
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Figure 18A. Simultaneous group, acute model (100x) 
 
 
Figure 18B. Simultaneous group, acute model (400x) 
59 
 
 
Figure 19A. Treatment group, acute model (100x) 
 
 
Figure 19B. Treatment group, acute model (400x) 
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Figure 20. Disease control, chronic model (400x) 
 
Figure 21A. Preventive group, chronic model (100x) 
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Figure 21B. Preventive group, chronic model (400x) 
 
 
Figure 22A. Simultaneous group, chronic model (100x) 
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Figure 22B. Simultaneous group, chronic model (400x) 
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Tables 
Table 1.  
Experimental and Control Groups 
Experimental group Abbreviated notation 
Vehicle control Healthy control 
Disease control DSS control 
Coco food at 60 mg/kg body weight  Test group (preventive)  
Coco food at 60 mg/kg body weight  Test group (simultaneous) 
Coco food at 60 mg/kg body weight  Test group (treatment) 
 
Table 2.  
Acute Model General Timetable 
Days DSS and Coco Administration 
0 1
st
 dose of DSS 
2 2
nd
  dose of DSS 
4 3
rd
  dose of DSS 
6 (DSS remove) Coco treatment 
14 Termination day 
 
Table 3.  
Chronic Model General Timetable 
Days DSS and Coco Administration 
0–2 DSS  (given to all groups) 
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3–8 Water (given to all groups) 
9–11 DSS  (given to all groups) 
12–17 Water (given to all groups) 
18–20 DSS (given to all groups) 
21–26 Water (given to all groups) 
27–29 DSS (given to all groups) 
30–35 Water (given to all groups) 
36–60 
Coco food given to test groups/normal chow given to DSS and water 
control group 
Day 60 Termination day 
 
Table 4. 
Dehydration Protocol for Isolated Colon Tissue 
1 Fix in 10 volumes of fixative: 18–24 hours 
2 Rinse 3 times in 50% ethanol 
3 Transfer to 50% ethanol for 1 hour 
4 Transfer to 70% ethanol for 1 hour 
5 Transfer to 95% ethanol for 1 hour 
6 Transfer to 100% ethanol for 1 hour 
7 Transfer to xylene for 45 minutes 
8 Transfer to xylene plus dissolved paraffinwax for 45 
minutes 
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9 Transfer to melted paraffin plus ethanol 
for 45 minutes 
10 Transfer to melted paraffin for 45 minutes 
11 Embed in wax block (allow to cool) 
 
Table 5. 
Hematoxylin and Eosin Staining Protocol for Microtome Sections 
 Station Solution Time 
 1 Xylene 3 minutes 
 2 Xylene 3 minutes 
 3 Xylene 3 minutes 
 4 100% ethanol 1 minute 
 5 100% ethanol 1 minute 
 6 100% ethanol 1 minute 
 7 95% ethanol 1 minute 
 8 Running tap water rinse Briefly 
 9 Deionized water Rinse 
 10 Hematoxylin 2.5 minutes 
 11 Running tap water rinse Rinse off excess stain 
 12 Acid alcohol 20 seconds to 1 minute 
 13 Running tap water rinse Agitate 30 seconds 
 14 Bluing reagent 1 minute 
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 15 Running tap water rinse 1 minute 
 16 95% ethanol Rinse 
 17 Eosin-Y 1.5 minutes 
 18 100% ethanol 1 minute 
 19 100% ethanol 1 minute 
 20 100% ethanol 1 minute 
 21 Xylene 1 minute 
 22 Xylene 1 minute 
 23 Xylene 1 minute 
 
Table 6. 
Scale for Disease Activity Index  
% Change in 
Body Weight 
Colorectal 
Length 
Fecal Occult 
Blood 
Stool 
Consistency 
Disease 
Activity 
Index (DAI) 
≥0-5% gain ≥10cm Negative Normal; 0 0 
≥ 0-5% loss ≥9.3cm Mild; +ve 1 1 
≥5-10% loss 
≥9.1cm 
 Moderate; 
++ve 2 2 
≥10-15% loss 
≥9cm 
Prolapse; 
+++ve 3 3 
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Appendix 
Enzyme-linked immuno sorbent assay (ELISA) Protocol. 
TNF-α. 
1) PBS (Phosphate Buffer Saline): 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 
1.5 mM KH2PO4, pH 7.2-7.4, 0.2 μm filtered. Add 9.6 g of PBS in 1 L of Type I 
purified water. 
2) Wash Buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4. Add 0.5 mL Tween 20 in 1 L 
of PBS. 
3) Reagent Diluent: 1% BSA (bovine serum albumin) in PBS, pH 7.2-7.4, 0.2 μm 
filtered. Add 10 g BSA in 1 L of PBS. 
4) Substrate Solution: 1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbenzidine).  
5) Stop Solution: 2 N H2SO4 
6) Capture Antibody: 144 μg/mL of goat anti-mouse TNF-α was reconstituted with 
1.0 mL of PBS.  
7) Detection Antibody: 36 μg/mL of biotinylated goat anti-mouse TNF-α was 
reconstituted with 1.0 mL of reagent diluent.  
8) Standard: 280 ng/mL of recombinant mouse TNF-α was reconstituted with 0.5 
mL of reagent diluent. A seven-point standard curve using two-fold serial 
dilutions in reagent diluent and a high standard of 2,000 pg/mL was used. 
9) Streptavidin-HRP: 1.0 mL of streptavidin conjugated to horseradish-peroxidase. 
Diluted to the working concentration specified on the vial label using reagent 
diluent (1:1 mixture). 
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Plate preparation protocol:                                                                                                           
1) The capture antibody was diluted to the working concentration in PBS without 
carrier protein. A 96-well microplate was immediately coated with 100 μL per 
well of the diluted capture antibody. The plate was sealed with paraffin film and 
incubated overnight at room temperature. 
a. Calculations for diluting the capture antibody to a working concentration 
of 0.8 μg/mL in PBS, without carrier protein: 
   
LV
mL
mL
g
V
mL
g


11.11
0.2
8.0144
1
1













 
11.11 μL of TNF-α capture antibody were diluted in 2.0 
mL of PBS. 
2) Each well was aspirated and washed with wash buffer, repeating the process two 
times for a total of three washes. Each well was washed by filling each well with 
wash buffer (400 μL) using a squirt bottle. Complete removal of liquid at each 
step was essential for good performance. After the last wash, any remaining wash 
buffer was removed by aspirating or by inverting the plate and blotting it against 
clean paper towels. 
3) Plates were blocked by adding 300 μL of reagent diluent to each well. Plates were 
incubated at room temperature for a minimum of 1 hour. 
4) The aspiration/wash was repeated as in step 2. The plates were then ready for 
sample addition.  
Assay Procedure:  
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1) 100 μL of sample or standard was added in reagent diluent, or another appropriate 
diluents, to each well. The microplate was covered with an adhesive strip and 
incubated for two hours at room temperature. 
a. 1.429 μL of standard TNF-α was diluted in 200 μL reagent diluent. 
b. The serial dilution was performed for the construction of the seven-point 
standard curve.  
c. Serum samples were diluted in a 1:1 ratio with reagent diluent. For 
example, 100 μL of a serum sample was diluted in 100 μL of reagent 
diluent for a total volume of 200 μL to be divided into two wells with 100 
μL of diluted sample per well. 
2) The aspiration/wash was repeated as in step 2 of plate preparation. 
3) 100 μL of the detection antibody, diluted in reagent diluent, was added to each 
well. The microplate was covered with a new adhesive strip and incubated for two 
hours at room temperature. 
a. 11.11 μL of detection antibody were diluted in 2.0 mL reagent diluent. 
4) The aspiration/wash was repeated as in step 2 of plate preparation. 
5) 100 μL of the working dilution of Streptavidin-HRP was added to each well. The 
microplate was covered and incubated for 20 minutes at room temperature. The 
microplate was kept out of direct light.  
a. The Streptavidin-HRP was diluted in a 1:1 ratio. 
6) The aspiration/wash was repeated as in step 2. 
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7) 100 μL of substrate solution was added to each well. The microplate was 
incubated for 20 minutes at room temperature. The microplate was kept out of 
direct light. 
8) 50 μL of stop solution was added to each well. The plate was gently tapped to 
ensure thorough mixing. 
9) The optical density of each well was determined immediately, using a microplate 
reader (Synergy H1 Hybrid Multi-Mode Microplate Reader from BioTek U.S., 
Winooski, VT) set to 540 nm. 
IL-17. 
1) Reagent diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 μm filtered. Added 10 g BSA 
in 1 L PBS.  
2) Capture antibody: 360 μg/mL of rat anti-mouse IL-17 was reconstituted with 1.0 
mL of PBS.  
3) Detection antibody: 144 μg/mL of biotinylated goat anti-mouse IL-17 was 
reconstituted with 1.0 mL of reagent diluent.  
4) Standard: 160 ng/mL of recombinant mouse IL-17 when reconstituted with 0.5 
mL of reagent diluent. The standard was allowed to sit for a minimum of 15 
minutes with gentle agitation prior to making dilutions. A seven-point standard 
curve using two-fold serial dilutions in reagent diluent, with a high standard of the 
recommended 1,000 pg/mL. 
5) Streptavidin-HRP: 1.0 mL of streptavidin conjugated to horseradish-peroxidase. 
6) Plate preparation methods were followed as outlined above. 
Assay Procedure: 
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1) 2.5 μL of standard IL-17 were diluted in 400 μL reagent diluent. The serial 
dilution was performed for the construction of the seven-point standard curve. 
2) Assay procedure was conducted as outlined above. 
IL-6. 
1) Reagent diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 μm filtered. Added 10 g BSA 
in 1 L PBS.  
2) Capture antibody: 360 μg/mL of rat anti-mouse IL-6 was reconstituted with 1.0 
mL of PBS.  
3) Detection antibody: 144 μg/mL of biotinylated goat anti-mouse IL-6 was 
reconstituted with 1.0 mL of reagent diluent.  
4) Standard: 160 ng/mL of recombinant mouse IL-6 when reconstituted with 0.5 mL 
of reagent diluent. The standard was allowed to rest for a minimum of 15 minutes 
and gently agitated prior to making dilutions. A seven-point standard curve using 
two-fold serial dilutions in reagent diluent, with the recommended high standard 
of 1,000 pg/mL. 
5) Streptavidin-HRP: 1.0 mL of streptavidin conjugated to horseradish-peroxidase.  
6) Plate preparation methods were followed as outlined above. 
Assay Procedure: 
1) 1) 2.5 μL of standard IL-6 were diluted in 400 μL reagent diluent. The serial 
dilution was performed for the construction of the seven-point standard curve.  
2) 2) The assay procedure was followed as outlined above. 
 
 
72 
 
IFN-γ. 
The PBS and wash buffer were prepared as outlined above, using the 
TNF-α kit. 
1) Block Buffer: 1% BSA in PBS with 0.05% NaN3. 
a. 1% BSA: 5 grams of BSA were added in 500 mL PBS 
b. 0.05% NaN3: 0.25 grams of NaN3 were added in 500 mL PBS 
c. 1% BSA solution was mixed with the 0.05% NaN3 solution. 
2) Reagent diluent: 0.1% BSA in PBS, 0.05% Tween 20 in Tris-buffered Saline (20 
mM Trizma Base, 150 mM NaCl), pH 7.2-7.4, 0.2 μm filtered. 
a. Made Tris-buffered saline: 
i. 1.2114 grams Tris Buffer was added in 500 mL Type I purified 
water 
ii. 4.383225 grams NaCl was added in 500 mL Type I purified water 
iii. The Tris Buffer solution was mixed with the NaCl solution 
b. Made reagent diluent: 
i. 0.5 grams of BSA and 0.25 mL of 0.05% Tween 20 were added 
into the Tris-buffered saline solution. 
3) Substrate solution and stop solution were added as outlined above. 
4) Capture Antibody: 720 μg/mL of rat anti-mouse IFN-γ was reconstituted with 1.0 
mL of PBS.  
5) Detection Antibody: 18 μg/mL of biotinylated goat anti-mouse IFN-γ when 
reconstituted with 1.0 mL of reagent diluent.  
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6) Standard: 205 ng/mL of recombinant mouse IFN-γ when reconstituted with 0.5 
mL of reagent diluent. The standard was allowed to rest for a minimum of 15 
minutes and gently agitated prior to making dilutions. A seven-point standard 
curve using two-fold serial dilutions in reagent diluent and a high standard of 
2,000 pg/mL was plotted. 
7) Streptavidin-HRP: 1.0 mL of streptavidin conjugated to horseradish-peroxidase.  
8) Plate preparation :  Capture antibody was prepared as outlined above. 11.11 μL of 
IFN-γ capture antibody was diluted in 2.0 mL of PBS and plate preparation 
methods were followed as outlined above. 
Assay Procedure:  
1) 100 μL of sample or standards in reagent diluent, or other appropriate diluent, 
were added to each well. Each microplate was covered with an adhesive strip and 
incubated two hours at room temperature. 1.95 μL of standard IFN-γ was diluted 
in 200 μL reagent diluent. 11.11 μL of detection antibody was diluted in 2.0 mL 
reagent diluent.  
2) The assay procedure was followed as outlined above 
IL-1β. 
The PBS and wash buffer were prepared as outlined above, using the 
TNF-α kit. 
1) Block Buffer: 1% BSA in PBS with 0.05% NaN3. 
a. 1% BSA: 5 grams of BSA were added in 500 mL PBS 
b. 0.05% NaN3: 0.25 grams of NaN3 were added in 500 mL PBS 
c. 1% BSA solution was mixed with the 0.05% NaN3 solution. 
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2) Reagent diluent: 0.1% BSA in PBS, 0.05% Tween 20 in Tris-buffered Saline (20 
mM Trizma Base, 150 mM NaCl), pH 7.2-7.4, 0.2 μm filtered. 
a. Made Tris-buffered saline: 
i. 1.2114 grams Tris Buffer was added in 500 mL Type I purified 
H20 
ii. 4.383225 grams NaCl was added in 500 mL Type I purified H2O 
iii. The Tris Buffer solution was mixed with the NaCl solution 
b. Made reagent diluent: 
i. 0.5 grams of BSA and 0.25 mL of 0.05% Tween 20 were added 
into the Tris-buffered saline solution. 
3) Substrate solution and stop solution were added as outlined above. 
4) Capture Antibody: 720 μg/mL of rat anti-mouse IL-1β was reconstituted with 1.0 
mL of PBS.  
5) Detection Antibody: 18 μg/mL of biotinylated goat anti-mouse IL-1β when 
reconstituted with 1.0 mL of reagent diluent.  
6) Standard: 205 ng/mL of recombinant mouse IL-1β when reconstituted with 0.5 
mL of reagent diluent. The standard was allowed to rest for a minimum of 15 
minutes and gently agitated prior to making dilutions. A seven-point standard 
curve using two-fold serial dilutions in reagent diluent and a high standard of 
2,000 pg/mL was plotted. 
7) Streptavidin-HRP: 1.0 mL of streptavidin conjugated to horseradish-peroxidase.  
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8) Plate preparation: Capture antibody was prepared as outlined above. 11.11 μL of 
IL-1β capture antibody was diluted in 2.0 mL of PBS and plate preparation 
methods were followed as outlined above. 
Assay Procedure:  
1) 100 μL of sample or standards in reagent diluent, or an appropriate diluents, were 
added to each well. Each microplate was covered with an adhesive strip and 
incubated two hours at room temperature. 1.95 μL of standard IL-1β was diluted 
in 200 μL reagent diluent. 11.11 μL of detection antibody was diluted in 2.0 mL 
reagent diluent.  
2) The assay procedure was followed as outlined above. 
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